Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Dyne Therapeutics Inc’s stock clocked out at $20.28, down -1.79% from its previous closing price of $20.65. In other words, the price has decreased by -$1.79 from its previous closing price. On the day, 2.57 million shares were traded. DYN stock price reached its highest trading level at $20.995 during the session, while it also had its lowest trading level at $20.14.
Ratios:
To gain a deeper understanding of DYN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.47 and its Current Ratio is at 13.47. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.17.
On August 25, 2025, Raymond James Upgraded its rating to Strong Buy which previously was Outperform but kept the price unchanged to $35.
On June 24, 2025, Bernstein started tracking the stock assigning a Mkt Perform rating and target price of $13.Bernstein initiated its Mkt Perform rating on June 24, 2025, with a $13 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 05 ’25 when Kerr Douglas bought 880 shares for $20.72 per share.
Cox John bought 2,662 shares of DYN for $55,150 on Dec 05 ’25. On Dec 05 ’25, another insider, Cox John, who serves as the CEO & President of the company, sold 2,662 shares for $20.72 each. As a result, the insider received 55,157 and left with 196,877 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DYN now has a Market Capitalization of 2896484864 and an Enterprise Value of 2225063680.
Stock Price History:
The Beta on a monthly basis for DYN is 1.31, which has changed by -0.2926404 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, DYN has reached a high of $29.72, while it has fallen to a 52-week low of $6.36. The 50-Day Moving Average of the stock is 10.85%, while the 200-Day Moving Average is calculated to be 54.69%.
Shares Statistics:
It appears that DYN traded 2.62M shares on average per day over the past three months and 2415140 shares per day over the past ten days. A total of 142.61M shares are outstanding, with a floating share count of 104.94M. Insiders hold about 26.52% of the company’s shares, while institutions hold 83.58% stake in the company. Shares short for DYN as of 1763078400 were 17111938 with a Short Ratio of 6.54, compared to 1760486400 on 17097410. Therefore, it implies a Short% of Shares Outstanding of 17111938 and a Short% of Float of 13.370000000000001.
Earnings Estimates
. The current rating of Dyne Therapeutics Inc (DYN) is the result of assessments by 10.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.85, with high estimates of -$0.75 and low estimates of -$1.0.
Analysts are recommending an EPS of between -$3.39 and -$3.83 for the fiscal current year, implying an average EPS of -$3.57. EPS for the following year is -$3.43, with 12.0 analysts recommending between -$3.08 and -$4.32.
